Is Retatrutide FDA Approved?
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Back to the Retatrutide Hub · See also: Dosage · vs Tirzepatide
No. Retatrutide is not FDA approved as of May 2026 — and not approved by the EMA or any other regulator. It is an investigational drug in Phase 3 trials (Eli Lilly's TRIUMPH program) and cannot be lawfully prescribed or sold as a medicine. The only lawful way to access it is by enrolling in an active clinical trial.
A regulatory submission is widely expected around late 2026, which would put a realistic approval decision in the 2027–2028 window. None of these dates are confirmed by Lilly or the FDA, and drug timelines slip routinely. Treat any specific "release date" online as speculation.
Where it is in development
Retatrutide is being tested in the TRIUMPH Phase 3 program, which spans more than 5,800 participants across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low-back pain, fatty-liver disease, and cardio-renal outcomes. The first readout, TRIUMPH-4, reported in December 2025; a Phase 3 diabetes readout (TRANSCEND-T2D-1) followed in March 2026. Seven additional Phase 3 readouts are expected through 2026. Only once that full data package is assembled would Lilly file a New Drug Application (NDA).
Realistic timeline
| Stage | Status / expectation |
|---|---|
| Phase 2 (obesity, T2D, MASLD) | ✅ Complete, published 2023–2024 |
| TRIUMPH-4 — first Phase 3 readout | ✅ Topline Dec 2025 (28.7% weight loss) |
| TRANSCEND-T2D-1 — Phase 3 diabetes | ✅ Topline March 2026 |
| Remaining TRIUMPH Phase 3 readouts | ⏳ Through 2026 |
| FDA submission (NDA) | ⏳ Anticipated ~late 2026 (not confirmed) |
| FDA review | ⏳ Typically ~10 months after filing |
| Possible approval decision | ⏳ Estimated 2027–2028 (not confirmed) |
What still has to happen
Three things, in order: (1) the remaining 2026 Phase 3 trials need to read out with efficacy and safety that hold up at scale — including clarity on the new dysesthesia signal seen in TRIUMPH-4; (2) Lilly has to compile and file the NDA; and (3) the FDA has to complete its review. A safety surprise, a request for more data, or manufacturing questions could each push the timeline back.
Context: how fast this can move
Approvals in this category can move quickly when the FDA prioritizes them. Lilly's oral GLP-1 pill orforglipron (Foundayo) became the fastest new-molecular-entity approval since 2002 — read our news coverage of the orforglipron approval. That doesn't guarantee a fast path for retatrutide (a different molecule with a larger, more complex program and a fresh safety signal), but it shows the regulatory environment is receptive to high-impact obesity drugs.
Until then — access & legality
Because it is not approved, retatrutide cannot be prescribed for weight loss, and it sits on the FDA's restricted list for compounding, so compounding pharmacies are not a lawful route either. The only legal access is a clinical trial, where it's provided under supervision at no cost. Products sold online as "research chemicals" are unregulated, of unverified identity and purity, and fall outside any approved medical framework. For the broader rules, see Are Peptides Legal? and the full cost & access section on the hub.
Frequently asked questions
Is retatrutide approved anywhere in the world?
No. As of May 2026 it has no regulatory approval in any country; it is investigational everywhere.
What's the earliest it could be approved?
Most observers cite 2027 as the earliest realistic window, possibly 2028 — contingent on the 2026 readouts and FDA review. Nothing is confirmed.
Will it be approved for diabetes too, or just obesity?
The program covers both, plus other conditions. Which indications appear on an eventual label depends on which trials succeed; obesity and type 2 diabetes are the lead indications.
Does a clinical-trial readout mean it's approved?
No. Positive topline results are a milestone toward approval, not approval itself. The FDA reviews the complete package before any decision.
Sources
- Eli Lilly & Company. TRIUMPH-4 Phase 3 topline results. News release, December 11, 2025.
- Eli Lilly & Company. TRANSCEND-T2D-1 Phase 3 topline. Company communication, March 2026.
- ClinicalTrials.gov — TRIUMPH program registrations (e.g., NCT05882045).
- U.S. FDA. Bulks-list determinations affecting peptide compounding (503A/503B), 2023–2026.
Medical disclaimer: Education only, not medical advice. Retatrutide is investigational and not approved for use. Consult a licensed clinician.